ABBVIE

Roche's experimental Parkinson’s drug, prasinezumab, failed another key trial but shows potential in levodopa users, prompting further exploration. Despite mixed results, Roche plans continued studies and data evaluation.

Rising ACR20 response rates in placebo arms of rheumatoid arthritis trials may be linked to global recruitment shifts, with recent trials including more patients from less affluent countries.

The 'Macular Edema - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of global clinical trials on Macular Edema, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, and provides enrollment trends and recent news.

Sanofi and Teva announced positive phase IIb RELIEVE UCCD study results for duvakitug, an anti-TL1A therapy for Ulcerative Colitis and Crohn's disease, meeting primary endpoints. Plans for a late-stage study and detailed results presentation are underway. Shares of both companies surged post-announcement.

UCB is discontinuing minzasolmin development for Parkinson’s disease after the ORCHESTRA study failed to meet endpoints. The company will focus on glovadalen (UCB0022) for symptom treatment. Stock prices briefly dropped but later recovered.

The MET targeting therapies market is poised for significant growth by 2034 due to rising cancer diagnoses, increased awareness, and numerous therapies in clinical trials. Key players include AstraZeneca, AbbVie, and Regeneron, with therapies like ORPATHYS and Telisotuzumab Vedotin in development. Regulatory approvals and precision medicine advancements are driving market dynamics, though challenges like pricing and reimbursement persist.

AbbVie announced positive Phase III TEMPO-2 trial results for tavapadon, a D1/D5 partial agonist for early Parkinson’s disease, showing significant improvements in MDS-UPDRS scores and safety. KOLs praise its versatility and potential for dyskinesia, but market competition from existing dopamine agonists poses a challenge. Tavapadon’s success may hinge on its safety profile and differentiation in a crowded market, with expected market entry in 2028.

Janssen-Cilag International NV submitted a Type II variation application to the EMA for IMBRUVICA® (ibrutinib) in combination with R-CHOP for previously untreated mantle cell lymphoma (MCL) patients eligible for autologous stem cell transplant. Supported by the TRIANGLE study, ibrutinib-based regimens showed improved efficacy over standard care, offering a potential alternative to transplant.

The Global Clinical Trial Investigative Site Network Market is projected to grow from US$ 8.1 billion in 2023 to US$ 17.2 billion by 2033, driven by increasing complexity in clinical trials and demand for efficient patient recruitment. North America leads with a 39.6% share, while oncology dominates therapeutic areas with a 40% share. Phase III trials hold a 50% share, and pharmaceutical & biopharmaceutical companies dominate with a 60% share. Opportunities include leveraging digital technologies and data analytics, decentralized trials, and partnerships like Lupus Therapeutics with AbbVie.

Teva and Sanofi's experimental drug duvakitug showed 'best-in-class potential' in Phase 2 trials for inflammatory bowel disease, with significant symptom improvement in ulcerative colitis and Crohn’s disease patients. The drug targets TL1A protein, a focus for several pharma companies. Teva and Sanofi plan to advance to Phase 3 pending regulatory discussions, with Sanofi set to pay Teva $600 million upon initiation.